PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Lire la suite
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Visite du médecin | prix sur demande |
Traitement du sang de cordon ombilical | $7000 - $9000 |
EXPERIENCE*
2019 - Present, Istanbul/Istanbul/Turkey
MEMORIAL ATAŞEHİR HOSPITAL
General Surgeon
2012 - 2019, Diyarbakır/Diyarbakır/Turkey
DİCLE UNIVERSITY FACULTY OF MEDICINE
General Surgeon
2011 - 2012, Van/Van/Turkey
VAN REGIONAL TRAINING AND RESEARCH HOSPITAL
General Surgeon
2009 - 2011, Van/Van/Turkey
HAKKARİ STATE HOSPITAL
General Surgeon
2004 - 2009, Van/Van/Turkey
YÜZÜNCÜYIL UNIVERSITY FACULTY OF MEDICINE
General Surgeon
2002 - 2004, Van/Van/Turkey
HACIBEKİR HEALTH CENTER
General Practitioner
*EDUCATION*
2018 - 2019, Diyarbakır/Turkey
Associate Professor
2015, Ohio/USA
OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
Neck Dissection Training
2012 - 2018, Diyarbakır/Turkey
Assistant Professor
1996 - 2002, Adana/Turkey
ÇUKUROVA UNIVERSITY
FACULTY OF MEDICINE - Medical Doctor Education
Lire la suiteEXPERIENCE*
2019 - Present, Istanbul/Istanbul/Turkey
MEMORIAL ATAŞEHİR HOSPITAL
General Surgeon
2012 - 2019, Diyarbakır/Diyarbakır/Turkey
DİCLE UNIVERSITY FACULTY OF MEDICINE
General Surgeon
2011 - 2012, Van/Van/Turkey
VAN REGIONAL TRAINING AND RESEARCH HOSPITAL
General Surgeon
2009 - 2011, Van/Van/Turkey
HAKKARİ STATE HOSPITAL
General Surgeon
2004 - 2009, Van/Van/Turkey
YÜZÜNCÜYIL UNIVERSITY FACULTY OF MEDICINE
General Surgeon
2002 - 2004, Van/Van/Turkey
HACIBEKİR HEALTH CENTER
General Practitioner
*EDUCATION*
2018 - 2019, Diyarbakır/Turkey
Associate Professor
2015, Ohio/USA
OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
Neck Dissection Training
2012 - 2018, Diyarbakır/Turkey
Assistant Professor
1996 - 2002, Adana/Turkey
ÇUKUROVA UNIVERSITY
FACULTY OF MEDICINE - Medical Doctor Education
Dr. Antonia Artigues-Barcelo is an Internal Medicine Consultant with more than 20 years of experience in the field of Internal Medicine.
After completing her Medical Degree from Universitat Autonoma in Barcelona, Spain, she acquired her Specialisation in Internal Medicine from Hospital Universitari Son Dureta and Hospital Clinic in Barcelona, both in Spain. She has extensive experience in Internal Medicine in inpatient and outpatient settings.
Before moving to the UAE, she was practicing in both private and government Hospitals in Spain, where she implemented different projects, including Autoimmune Systemic Diseases Unit, Palliative Care Unit, and a multidisciplinary management program of hip fractures in older patients. She was also the HOD in Internal Medicine Department.
Since she moved to the UAE, she has been working as an Internal Medicine Consultant in well-known Clinics and Hospitals in Dubai. She has also been an Adjunct Associated Professor at Mohammed Bin Rashid University (MBRU).
Her scope of expertise includes general internal medicine conditions, gastrointestinal disorders, respiratory diseases, anaemias, thyroid conditions, as well as, infection diseases, autoimmune systemic conditions and prevention, detection, and treatment of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidaemia. She also carries out general check-ups.
She is a member of the Spanish Medical Council and the Internal Medicine Spanish Association, as well as, member of Middle East and North Africa Stroke Organization.
EXPERTISE:
Dr. Antonia Artigues-Barcelo is an Internal Medicine Consultant with more than 20 years of experience in the field of Internal Medicine.
After completing her Medical Degree from Universitat Autonoma in Barcelona, Spain, she acquired her Specialisation in Internal Medicine from Hospital Universitari Son Dureta and Hospital Clinic in Barcelona, both in Spain. She has extensive experience in Internal Medicine in inpatient and outpatient settings.
Before moving to the UAE, she was practicing in both private and government Hospitals in Spain, where she implemented different projects, including Autoimmune Systemic Diseases Unit, Palliative Care Unit, and a multidisciplinary management program of hip fractures in older patients. She was also the HOD in Internal Medicine Department.
Since she moved to the UAE, she has been working as an Internal Medicine Consultant in well-known Clinics and Hospitals in Dubai. She has also been an Adjunct Associated Professor at Mohammed Bin Rashid University (MBRU).
Her scope of expertise includes general internal medicine conditions, gastrointestinal disorders, respiratory diseases, anaemias, thyroid conditions, as well as, infection diseases, autoimmune systemic conditions and prevention, detection, and treatment of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidaemia. She also carries out general check-ups.
She is a member of the Spanish Medical Council and the Internal Medicine Spanish Association, as well as, member of Middle East and North Africa Stroke Organization.
EXPERTISE:
Expérience
2016 - 2019 Hôpital privé Gebze Konak
2014 - 2015 Hôpital privé Medicana Çamlıca
2013 - 2014 Hôpital privé de Batman
2011 - 2013 Hôpital régional d'État de Batman
Université d'Üsküdar
Faculté de médecine de l'Université de Gazi
éducation
2011 Faculté de médecine, médecine physique et réadaptation de l'Université Bezmialem Vakıf
2005 Université de Marmara, Faculté de médecine en anglais
Lire la suiteExpérience
2016 - 2019 Hôpital privé Gebze Konak
2014 - 2015 Hôpital privé Medicana Çamlıca
2013 - 2014 Hôpital privé de Batman
2011 - 2013 Hôpital régional d'État de Batman
Université d'Üsküdar
Faculté de médecine de l'Université de Gazi
éducation
2011 Faculté de médecine, médecine physique et réadaptation de l'Université Bezmialem Vakıf
2005 Université de Marmara, Faculté de médecine en anglais
Chef du département de physiologie clinique, thérapeute
Chef du département de physiologie clinique, thérapeute
Lire la suiteChef du département de physiologie clinique, thérapeute
Chef du département de physiologie clinique, thérapeute
Le professeur Marcus Dukes est un spécialiste de la radiologie diagnostique et des thérapies mini-invasives.
Le professeur Marcus Dukes est un spécialiste de la radiologie diagnostique et des thérapies mini-invasives.
Physiatre consultant expérimenté travaillant actuellement à l'hôpital de réadaptation de Beroun, avec une expérience antérieure en tant que médecin de réadaptation, consultant en médecine de réadaptation, physiothérapeute en chef, directeur médical et médecin généraliste. Il est titulaire d'un diplôme de docteur en médecine de l'université Masaryk, ainsi que de certifications en médecine physique et de réadaptation et en chirurgie générale. Il a l'habitude de donner des conférences et est l'auteur de nombreuses publications.
Lire la suitePhysiatre consultant expérimenté travaillant actuellement à l'hôpital de réadaptation de Beroun, avec une expérience antérieure en tant que médecin de réadaptation, consultant en médecine de réadaptation, physiothérapeute en chef, directeur médical et médecin généraliste. Il est titulaire d'un diplôme de docteur en médecine de l'université Masaryk, ainsi que de certifications en médecine physique et de réadaptation et en chirurgie générale. Il a l'habitude de donner des conférences et est l'auteur de nombreuses publications.
Le médecin est membre de plusieurs organisations professionnelles, dont l'Association professionnelle des internistes allemands, la Société allemande de médecine interne, la Société allemande de pneumologie et de médecine respiratoire, la Société allemande du sommeil, la Fondation allemande du poumon, la Société respiratoire européenne, la Société pour la formation pulmonaire, le groupe de travail nord-allemand sur le carcinome bronchique et la Société nord-allemande de pneumologie.
Lire la suiteLe médecin est membre de plusieurs organisations professionnelles, dont l'Association professionnelle des internistes allemands, la Société allemande de médecine interne, la Société allemande de pneumologie et de médecine respiratoire, la Société allemande du sommeil, la Fondation allemande du poumon, la Société respiratoire européenne, la Société pour la formation pulmonaire, le groupe de travail nord-allemand sur le carcinome bronchique et la Société nord-allemande de pneumologie.
Le docteur Gazda a reçu une formation et un perfectionnement dans les domaines suivants :
La médecine nutritionnelle et la médecine du rajeunissement
Depuis 2011, Maria Gazda travaille à l'Institut de thérapie cellulaire.
Depuis 2011, Maria Gazda travaille à l'Institut de thérapie cellulaire.
Lire la suiteLe docteur Gazda a reçu une formation et un perfectionnement dans les domaines suivants :
La médecine nutritionnelle et la médecine du rajeunissement
Depuis 2011, Maria Gazda travaille à l'Institut de thérapie cellulaire.
Depuis 2011, Maria Gazda travaille à l'Institut de thérapie cellulaire.
Le médecin a été formé à l'université médicale nationale Bogomolets et à l'académie médicale nationale d'enseignement postuniversitaire portant le nom de P. L. Shupyk à Kiev.
Lire la suiteLe médecin a été formé à l'université médicale nationale Bogomolets et à l'académie médicale nationale d'enseignement postuniversitaire portant le nom de P. L. Shupyk à Kiev.
Le Dr Yaroslav Miroshnykov est un urologue, andrologue, sexologue et directeur du Renaissance Technology clinic Medical Center très expérimenté et qualifié, avec 22 ans d'expérience et de formation médicale. Il a reçu de nombreux prix et distinctions et possède une vaste expérience dans divers domaines médicaux.
Lire la suiteLe Dr Yaroslav Miroshnykov est un urologue, andrologue, sexologue et directeur du Renaissance Technology clinic Medical Center très expérimenté et qualifié, avec 22 ans d'expérience et de formation médicale. Il a reçu de nombreux prix et distinctions et possède une vaste expérience dans divers domaines médicaux.
Dr. Nazli KORKMAZ, une experte renommée dans le domaine de la chirurgie esthétique génitale. La clinique, située à Istanbul, en Turquie, est reconnue pour ses normes médicales exceptionnelles et son engagement envers le bien-être des patients. Le Dr Nazli Korkmaz, qui fonde ses traitements sur le principe de la "prise en charge de tous les aspects de la santé des femmes", adopte une approche globale du bien-être, de la sexualité et de l'esthétique des femmes, répondant aux besoins uniques des femmes tout au long de leur vie. Avec une équipe dévouée, le Dr Nazli KORKMAZ, chirurgien, assure une expérience confortable et professionnelle, offrant des résultats optimaux lorsque la patiente entre dans sa clinique. L'équipe médicale de la clinique reconnaît que chaque patiente a des besoins et des attentes qui lui sont propres. Par conséquent, elle personnalise chaque visite pour répondre aux besoins des patients, en fournissant des soins personnalisés à chaque étape.
Lire la suiteDr. Nazli KORKMAZ, une experte renommée dans le domaine de la chirurgie esthétique génitale. La clinique, située à Istanbul, en Turquie, est reconnue pour ses normes médicales exceptionnelles et son engagement envers le bien-être des patients. Le Dr Nazli Korkmaz, qui fonde ses traitements sur le principe de la "prise en charge de tous les aspects de la santé des femmes", adopte une approche globale du bien-être, de la sexualité et de l'esthétique des femmes, répondant aux besoins uniques des femmes tout au long de leur vie. Avec une équipe dévouée, le Dr Nazli KORKMAZ, chirurgien, assure une expérience confortable et professionnelle, offrant des résultats optimaux lorsque la patiente entre dans sa clinique. L'équipe médicale de la clinique reconnaît que chaque patiente a des besoins et des attentes qui lui sont propres. Par conséquent, elle personnalise chaque visite pour répondre aux besoins des patients, en fournissant des soins personnalisés à chaque étape.